What are the purchasing channels for Acalabrutinib in China?

Acalabrutinib (Acalabrutinib) is a targeted drug, a BTK inhibitor, mainly used to treat chronic lymphocytic leukemia (CLL) and other B cell malignant tumors. Acotinib has been launched in China and has been successfully included in the scope of medical insurance reimbursement, allowing patients to obtain the drug at a more favorable price. The purchase channels of acotinib in China mainly include hospital prescription and pharmacy sales.

In China, patients can purchase acotinib through the pharmacies of major hospitals, especially in oncology, hematology and other related departments, where this drug is usually available. Hospital purchase is the most common way, and patients need to purchase it with a doctor's prescription. The specification of acotinib is usually 100mg*8 tablets, and the price per box is about 20,000 yuan. Although the price is higher, because it is included in the reimbursement scope of medical insurance, eligible patients can pay part or all of the cost through medical insurance, thereby reducing the financial burden.

In addition to hospitals, acotinib can also be purchased on some online drug platforms, especially some legal drug e-commerce platforms. As China's pharmaceutical market gradually opens up, online purchasing has become a convenient choice for many patients. However, when purchasing online, you need to ensure the formality of the source of drugs to avoid purchasing fake and inferior drugs. Such platforms generally provide detailed instructions for drugs, and patients can learn about the relevant information and usage requirements of the drugs through the drug information on the platform.

For patients who need long-term medication, generic drugs of acotinib have also begun to gradually circulate in the domestic market. Generic drugs have roughly the same ingredients and efficacy as brand-name drugs, but are usually much cheaper. For example, the generic version of acotinib produced by Laos Pharmaceuticals is 100mg*60 tablets, and the price per box is about 2,000 yuan. The price is significantly lower than that of the original drug, making it suitable for some patients with limited financial conditions.

Reference materials:https://www.calquence.com/